Joshua Mitchell, MD, MSCI

Cardio-Oncologist

Joshua Mitchell

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Cardiotoxicity from cancer therapy, cancer survivorship, cardiomyopathy, prevention, general cardiology, cardiac amyloidosis

Primary Academic Title

Associate Professor of Medicine, Director of Cardio-Oncology Center of Excellence, Director, Cardio-Oncology Fellowship, Co-Director, Amyloid Center of Excellence, WashU Medicine

Board Certification

  • 2008: American Board of Internal Medicine

Training

  • 2008 - 2011: Resident, Internal Medicine, Walter Reed Army Medical Center, Washington D.C.
  • 2015 - 2018: Fellow, Cardiovascular Disease, WashU Medicine, St. Louis, MO
  • 2017 - 2018: Fellow, Cardio-oncology, WashU Medicine, St. Louis, MO

Education

  • 2008: MD, University of Texas Southwestern Medical Center, Dallas, TX

Research & Selected Publications

Research Interest

Elucidating the optimal prevention, screening, and management of adverse cardiac effects from cancer therapies and improving the diagnosis and management of patients with cardiac amyloid

Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer
Authors:

Han IS, Ko K, Zou JW, one or more additional authors omitted Mitchell JD, one or more additional authors omitted Ky B

Journal & Year:

J Thorac Oncol | 2026

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement
Authors:

Herrmann J, Barac A, Carver J, one or more additional authors omitted Mitchell JD

Journal & Year:

JAMA Oncol | 2026

Cardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review
Authors:

Raman HS, Mitchell J, Nohria A, Upshaw JN , LaCasce AS

Journal & Year:

JACC CardioOncol | 2025

CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis
Authors:

Mitchell JD, Pfeiffer M, Boehmer J, one or more additional authors omitted Cortes JE

Journal & Year:

Cardiooncology | 2025

Atrial fibrillation is associated with increased in-hospitality mortality during Chimeric Antigen Receptor T-cell therapy hospitalizations: a retrospective cohort study in the Unit…
Authors:

Baral N, Karki NR, Ladin DA, one or more additional authors omitted Mitchell JD

Journal & Year:

Cardiooncology | 2025

Atrial fibrillation or flutter in patients undergoing stem cell transplantation, in-hospital and post-discharge outcomes in a large nationwide sample across the United States
Authors:

Zaghlol R, Deych E, Manian N, Altibi A, Mitchell JD

Journal & Year:

Cardiooncology | 2025

ASO Author Reflections: Plasma Ceramide Levels Aid in Prognosis in Pancreatic Ductal Adenocarcinoma
Authors:

Mitchell JD, Peterson LR

Journal & Year:

Ann Surg Oncol | 2025

Severe Aortic Stenosis and Chronic Myeloid Leukemia: Considerations for Valve Management
Authors:

Cunningham R, Yoo SGK, Brescia AA, one or more additional authors omitted Mitchell JD

Journal & Year:

JACC CardioOncol | 2025